Gosset Ownership
Private
Employees
~18
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Promius Pharma General Information
Promius Pharma sold its rights for SERNIVO® (betamethasone dipropionate) Spray, 0.05% and assigned its rights to market and distribute PROMISEB® Topical Cream and TRIANEX® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States to Encore Dermatology in April 2019[1][6].
Contact Information
Primary Industry
Biotech
Corporate Office
Princeton, New Jersey
United States
United States
Drug Pipeline
betamethasone dipropionate
CommercialKey Partnerships
Encore Dermatology (buyer of their dermatology assets)[1][6]
Promius Pharma Funding
No funding data available
To view Promius Pharma's complete valuation and funding history, request access »